Notice: This company has been marked as potentially delisted and may not be actively trading. Intensity Therapeutics, Inc. Common stock (INTS) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesOwnershipShort InterestTrends Get the Latest News and Ratings for INTS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Intensity Therapeutics, Inc. Common stock and its competitors. Enter your email to sign up for newsletter Sign Up INTS Analyst Ratings Over TimeTypeCurrent Forecast11/22/23 to 11/21/241 Month Ago10/23/23 to 10/22/243 Months Ago8/24/23 to 8/23/241 Year Ago11/22/22 to 11/22/23Strong Buy1 Strong Buy rating(s)1 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy2 Buy rating(s)1 Buy rating(s)1 Buy rating(s)1 Buy rating(s)Hold0 Hold rating(s)0 Hold rating(s)0 Hold rating(s)0 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$8.50$12.00$12.00$12.00Forecasted Upside188.14% Upside259.28% Upside179.07% Upside433.33% UpsideConsensus RatingBuyStrong BuyBuyBuy New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! INTS Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History INTS Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Intensity Therapeutics, Inc. Common stock Stock vs. The CompetitionTypeIntensity Therapeutics, Inc. Common stockMedical CompaniesS&P 500Consensus Rating Score 3.33 2.80 2.50Consensus RatingBuyModerate BuyModerate BuyPredicted Upside188.14% Upside26,623.65% Upside8.50% UpsideNews Sentiment RatingVery Positive NewsSee Recent INTS NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails11/21/2024HC Wainwright2 of 5 starsS. RamakanthSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00+69.49%9/20/2024Brookline Capital Management2 of 5 starsK. RajaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/11/2024Benchmark2 of 5 starsR. WassermanSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSpeculative Buy ➝ Speculative Buy$12.00 ➝ $12.00+144.90%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:26 PM ET. INTS Forecast - Frequently Asked Questions What is Intensity Therapeutics, Inc. Common stock's forecast for 2025? According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Intensity Therapeutics, Inc. Common stock is $8.50, with a high forecast of $12.00 and a low forecast of $5.00. Should I buy or sell Intensity Therapeutics, Inc. Common stock stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intensity Therapeutics, Inc. Common stock in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" INTS shares. Does Intensity Therapeutics, Inc. Common stock's stock price have much upside? According to analysts, Intensity Therapeutics, Inc. Common stock's stock has a predicted upside of 188.14% based on their 12-month stock forecasts. Has Intensity Therapeutics, Inc. Common stock been upgraded by Wall Street analysts recently? Over the previous 90 days, Intensity Therapeutics, Inc. Common stock's stock had 1 upgrade by analysts. What analysts cover Intensity Therapeutics, Inc. Common stock? Intensity Therapeutics, Inc. Common stock has been rated by research analysts at Brookline Capital Management, and HC Wainwright in the past 90 days. Do Wall Street analysts like Intensity Therapeutics, Inc. Common stock more than its competitors? Analysts like Intensity Therapeutics, Inc. Common stock more than other "medical" companies. The consensus rating for Intensity Therapeutics, Inc. Common stock is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how INTS compares to other companies. Stock Forecasts and Research Tools Related Companies Instil Bio Stock Forecast Elutia Stock Forecast Acumen Pharmaceuticals Stock Forecast Cidara Therapeutics Stock Forecast Candel Therapeutics Stock Forecast Black Diamond Therapeutics Stock Forecast Fennec Pharmaceuticals Stock Forecast Coherus BioSciences Stock Forecast Compugen Stock Forecast Cardiff Oncology Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! This page (NASDAQ:INTS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intensity Therapeutics, Inc. Common stock Please log in to your account or sign up in order to add this asset to your watchlist. Share Intensity Therapeutics, Inc. Common stock With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
